Zydus Lifesciences Ltd share Price Today

Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines.

• Q3FY23 revenue break-up – US: 46.3%, India: 29.6%, Wellness: 9.9%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 14.2%
• Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with ₹ 100 crore+ sales

Zydus delivered good set of numbers, which beat our estimates.

• Revenues grew 19.8% YoY at ₹ 4362 crore
• EBITDA grew 27.2% YoY to ₹ 956 crore. EBITDA margins improved 127 bps YoY to 21.9%
• Adjusted net profit rose 22.8% YoY to ₹ 622.5 crore

Pharmaceuticals company Zydus Lifesciences announced Q1FY25 results:

• Total revenues grew 21% YoY to Rs 62,075 million, led by growth across businesses.
• India branded formulations business posted double-digit growth and outpaced the market growth both in the chronic and acute segments.
• Consumer Wellness business delivered an industry leading double-digit growth aided by improved demand scenario and extended summer.
• US formulations business registered a robust sequential and y-o-y growth driven by new launches and volume expansion in base portfolio.
• On the international markets front, demand scenario remained strong across key markets and drove the growth.
• EBITDA margin stood at 33.6%, up 430 bps YoY.
• Capex (organic) for the quarter: Rs 3,014 million.
• Net cash: Rs 18,922 million (at 30-Jun’24) vs 8,561 million (at 31-Mar’24)

Result PDF